JUPITER NEJM PDF

Tojazilkree There were no significant differences between the treatment groups with respect to muscle pain, muscle weakness, hepatic function, or renal function; however, the researchers noted small but statistically significant increases in the rate of physician-reported diabetes and glycated hemoglobin values in the rosuvastatin group, an effect that has also been seen in studies with other statins. The trial focused on patients with normal low-density lipoprotein LDL cholesterol levels but increased levels of high-sensitivity C-reactive protein hs-CRP. Because half of all vascular events occur in jupitter with normal or low levels of LDL cholesterol, JUPITER was designed to determine whether hs-CRP testing could identify these juupiter, and whether statin therapy could prevent cardiovascular events among them. In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.

Author:Doubar Tazshura
Country:Malawi
Language:English (Spanish)
Genre:Marketing
Published (Last):15 April 2015
Pages:401
PDF File Size:11.44 Mb
ePub File Size:19.33 Mb
ISBN:286-8-78079-344-5
Downloads:40628
Price:Free* [*Free Regsitration Required]
Uploader:Kigasida



Tojazilkree There were no significant differences between the treatment groups with respect to muscle pain, muscle weakness, hepatic function, or renal function; however, the researchers noted small but statistically significant increases in the rate of physician-reported diabetes and glycated hemoglobin values in the rosuvastatin group, an effect that has also been seen in studies with other statins.

The trial focused on patients with normal low-density lipoprotein LDL cholesterol levels but increased levels of high-sensitivity C-reactive protein hs-CRP.

Because half of all vascular events occur in jupitter with normal or low levels of LDL cholesterol, JUPITER was designed to determine whether hs-CRP testing could identify these juupiter, and whether statin therapy could prevent cardiovascular events among them. In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.

The trial was sponsored by AstraZenecathe marketer of Crestor rosuvastatin. We randomly assigned 17, apparently healthy men and women with low-density lipoprotein LDL cholesterol levels of less than mg per deciliter 3. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.

The trial was stopped after a median follow-up of 1. Am J Kidney Dis. Consistent effects were observed in all subgroups nehm. The rates of the primary end point were 0. They also raised concerns about conflict of interest in the trial design and leadership: Views Read Edit View history. Inresults presented at the American Heart Association meeting and published in the New England Journal jupitre Medicine found that patients with low-to-normal LDL cholesterol receiving rosuvastatin had a lower rate of major cardiovascular events.

Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. The trial was stopped early, after just 1. JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.

From Wikipedia, the free encyclopedia. The trial analyzed 17, patients without evidence of heart disease but with high CRP jupitfr. By using mupiter site, you agree to the Terms of Use and Privacy Policy. An I ntervention T rial E valuating R osuvastatin trial was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people jupiteer normal cholesterol levels.

Cardiovascular Quality and Outcomes. Michel de Lorgeril, et al.

ALTUN YARUK PDF

JUPITER trial

.

HP2 T16 PDF

.

Related Articles